$CLDX TSP Capital Management Group LLC Increases Position

New Post Public Reply Private Reply Replies (1) Message Board
fitzkarz
$CLDX TSP Capital Management Group LLC Increases Position in Celldex Therapeutics, Inc. (CLDX)

Posted by Reagan on Mar 31st, 2016 // No Comments

Celldex Therapeutics logoTSP Capital Management Group LLC boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 831,648 shares of the biopharmaceutical company’s stock after buying an additional 6,967 shares during the period. Celldex Therapeutics comprises approximately 7.0% of TSP Capital Management Group LLC’s holdings, making the stock its largest position. TSP Capital Management Group LLC owned approximately 0.84% of Celldex Therapeutics worth $13,040,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Bedell Frazier Investment Counseling LLC raised its stake in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Columbia Wanger Asset Management LLC raised its stake in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares in the last quarter. ProShare Advisors LLC raised its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter. Columbus Circle Investors raised its stake in Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares in the last quarter. Finally, Suffolk Capital Management LLC raised its stake in Celldex Therapeutics by 32.4% in the fourth quarter. Suffolk Capital Management LLC now owns 167,215 shares of the biopharmaceutical company’s stock worth $2,622,000 after buying an additional 40,906 shares in the last quarter.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at 3.60 on Thursday. The company has a 50-day moving average price of $5.40 and a 200-day moving average price of $11.39. The firm’s market cap is $355.33 million. Celldex Therapeutics, Inc. has a 12-month low of $2.96 and a 12-month high of $30.28.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.02. The firm earned $1.80 million during the quarter, compared to analyst estimates of $0.80 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 21.1% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics, Inc. will post ($1.33) earnings per share for the current year.

A number of analysts have commented on the stock. Roth Capital reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 7th. HC Wainwright reduced their price objective on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price objective (down from $28.00) on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $20.00.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newslette
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 79

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 12

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 75

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading

Top 5 Most Recently Viewed Articles

Vidrio Financial and Investcorp-Tages Enhance Partnership for Investment Solutions

Updated Category News Views 109

Vidrio Financial and Investcorp-Tages Expand Their Partnership Vidrio Financial, an AI-driven software solution designed for global institutional allocators, has announced an expanded partnership with Investcorp-Tages to enhance coverage in private market investment initiatives. This collaboration aims to provide advanced monitoring and data transparency in the...

Continue Reading
Linkers Industries Limited Schedules Initial IPO for Nasdaq Launch

Updated Category News Views 115

Linkers Industries Limited Commences Initial Public Offering Linkers Industries Limited (Nasdaq: LNKS), a prominent manufacturer and supplier of wire and cable harnesses, has officially announced the pricing of its initial public offering (IPO). This exciting development follows a well-organized plan aimed at expanding its operations and reach within the industry. Details...

Continue Reading
OutKick Reports Impressive Growth in Visitor Engagement Metrics

Updated Category News Views 187

OutKick's Impressive Q2 Performance In 2025, OutKick, a prominent multimedia sports platform, showcased remarkable growth from the first to the second quarter. The latest metrics reveal that average unique visitors across desktop and mobile platforms increased by 26%, totaling 6.2 million. Alongside this, the platform recorded a substantial rise in total views, soaring by...

Continue Reading
Celebrating David R. Walt's Achievement with Technology Medal

Updated Category News Views 274

David R. Walt Honored with National Medal of Technology and Innovation BILLERICA, Mass.-- Quanterix Corporation (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, proudly announces that David R. Walt has received the prestigious National Medal of Technology and Innovation. This honor is awarded by the President of the United States, celebrating individuals...

Continue Reading
HALO AirFinance Completes Successful Loan Transactions

Updated Category News Views 262

HALO AirFinance Finalizes Its Eighth Loan HALO AirFinance, a collaborative effort between GA Telesis and Tokyo Century Corporation, has successfully closed its eighth and final loan for Crestone Air Partners. This significant transaction involved the acquisition of a CFM56-7B engine, which has been leased to a European carrier. The completion of this deal highlights the...

Continue Reading